Company Overview - Averin Capital Acquisition Corp. is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily focusing on opportunities in the technology and health industries [2]. IPO Details - The company announced the pricing of its initial public offering (IPO) of 25,000,000 units at a price of $10.00 per unit, with units expected to be listed on the Nasdaq Global Market under the ticker symbol "ACAAU" starting February 19, 2026 [1]. - Each unit consists of one Class A ordinary share and one-sixth of one redeemable warrant, with each whole warrant allowing the holder to purchase one Class A ordinary share at a price of $11.50 per share [1]. - An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering, which is expected to close on February 20, 2026, subject to customary closing conditions [1]. - The underwriters have been granted a 45-day option to purchase up to an additional 3,750,000 units at the initial public offering price to cover over-allotments [1]. Management Team - The management team is led by David A. Berry as Chairman and Chief Executive Officer, and Alex Lau as Chief Financial Officer and Secretary. The Board of Directors includes Ulrik Schulze, Graeme Bell, and Mary T. Szela [3]. Underwriting - Deutsche Bank Securities Inc. is acting as the sole book-running manager for the offering [3]. Regulatory Information - A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on February 18, 2026 [5]. - The offering is being made only by means of a prospectus, which can be obtained from Deutsche Bank Securities Inc. or accessed via the SEC's website [4].
Averin Capital Acquisition Corp. Announces the Pricing of $250,000,000 Initial Public Offering